Key facts
- This page summarizes Robert E. Conway's Form 4 filing for ALPINE IMMUNE SCIENCES, INC..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jan 2023, 17:56.
Robert E. Conway - 03 Jan 2023 Form 4 Insider Report for ALPINE IMMUNE SCIENCES, INC.
- Form type
- 4
- Accepted by SEC
- 05 Jan 2023, 17:56:22 UTC
- Previous filing
- 19 Dec 2022
- Next filing
- 04 Jan 2024
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ James Paul Rickey, attorney-in-fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. Conway filed Form 4 for ALPINE IMMUNE SCIENCES, INC. on 05 Jan 2023.
Change
- Previous filing in this sequence was filed on 19 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALPN
transaction
Derivative
Stock Option (Right to buy)
Award
- Transaction value
- $0
- Shares
- +10,000
- Change %
- Price
- $0.000000
- Shares after
- 10,000
- Date
- 03 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,000
- Exercise price
- $7.43
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
Footnote F2
1/12th of the shares subject to the option become vested and exercisable on February 3, 2023 and 1/12 of the shares subject to the option shall vest monthly thereafter.